Clinical trials: Letrozole
Endometrial Cancer
Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
The goal of this clinical research study is to learn if the combination of RAD001 (everolimus) and Femara (letrozole) can help to control recurrent or progressive endometrial cancer.
- Trial name
- NCT01068249
- Testing
- Letrozole, RAD001 (Everolimus)
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Cancer of Breast
Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer
The investigators propose to influence estrogen receptor (ER) signaling by combining endocrine therapy with CDK4/6 inhibition along with trastuzumab in ER+/ human epidermal growth factor receptor 2 (HER2)+ early stage breast…
- Conditions
- Breast Cancer, Cancer of Breast, Breast Carcinoma
- Trial name
- PALTAN (NCT02907918)
- Testing
- Palbociclib, Letrozole, Trastuzumab
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Washington University School of Medicine
Bone Loss, Breast Cancer
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.
Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every…
- Trial name
- NCT00171340
- Testing
- Zoledronic acid, Letrozole
- Where
- 106 sites in Argentina, Australia and 26 more
- Volunteers
- 1,065 people
- Sponsor
- Novartis Pharmaceuticals
Atrophic Vaginitis, Breast Cancer
Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen
The purpose of this study is to see if Vagifem® 10mcg is safe for women who have had breast cancer. Vagifem is an estrogen product. It is a tiny tablet that is inserted into the vagina. It relieves vaginal dryness.
- Trial name
- NCT00984399
- Testing
- Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist
- Where
- 5 sites in United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer Metastatic
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
A Phase 2, open-label, multicenter international study will be performed to evaluate the efficacy of MCLA-128-based combinations. Three combination treatments will be evaluated, two in Cohort 1 and one in Cohort 2.
- Trial name
- NCT03321981
- Testing
- Zenocutuzumab, Trastuzumab, Vinorelbine
- Where
- 25 sites in United States, Belgium and 5 more
- Volunteers
- 105 people
- Sponsor
- Merus B.V.
Male Breast Cancer, Recurrent Breast Cancer
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving aromatase inhibitor (AI) therapy.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT01153672
- Testing
- vorinostat, laboratory biomarker analysis, biopsy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Washington
Metastatic ER+ Her2- Breast Cancer, Postmenopausal
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
The purpose of this study is to assess the safety and efficacy of oral abiraterone acetate plus oral prednisone and oral abiraterone acetate plus oral prednisone plus oral exemestane, each compared with oral exemestane alone, in…
- Trial name
- NCT01381874
- Testing
- Exemestane, Abiraterone acetate + Prednisone/ Prednisolone + Exemestane, Abiraterone acetate + Prednisone or Prednisolone
- Where
- 81 sites in United States, Belgium and 10 more
- Volunteers
- 297 people
- Sponsor
- Janssen Research & Development, LLC
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
This phase I/II trial studies the side effects and best dose of hydroxychloroquine when given together with palbociclib and letrozole before surgery in treating patients with estrogen receptor positive, HER2 negative breast…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT03774472
- Testing
- Hydroxychloroquine, Letrozole, Palbociclib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Letrozole in Preventing Breast Cancer in Postmenopausal Women
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Letrozole may be effective in preventing the development or recurrence of breast cancer in postmenopausal…
- Trial name
- WISE (NCT00090857)
- Testing
- Letrozole
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Dana-Farber Cancer Institute
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive
Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer
This phase II trial studies the side effects and how well letrozole and imatinib mesylate work in treating postmenopausal participants with estrogen or progesterone positive breast cancer that has spread to other places in the…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, KIT Positive, PDGFR Positive
- Trial name
- NCT00338728
- Testing
- Imatinib Mesylate, Letrozole
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphangioleiomyomatosis
Letrozole for Lymphangioleiomyomatosis
The hypothesis in this study is that estrogen suppression by an aromatase inhibitor in postmenopausal women with lymphangioleiomyomatosis (LAM) will prevent or delay progression of lung disease and result in a decrease in the…
- Trial name
- TRAIL (NCT01353209)
- Testing
- Letrozole
- Where
- 9 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of Cincinnati
Breast Cancer
Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT00573755
- Testing
- anastrozole, exemestane, letrozole
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Breast Cancer
Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- SOLE (NCT00553410)
- Testing
- Letrozole
- Where
- 164 sites in United States, Australia and 18 more
- Volunteers
- 4,884 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer, Estrogen Receptor Positive Tumor
To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)
This is a phase II open-label, multicentre, randomized trial. The study assesses the treatment of postmenopausal patients with hormone receptor positive/HER2 positive early breast cancer with neoadjuvant palbociclib in…
- Conditions
- Breast Cancer, Estrogen Receptor Positive Tumor, HER2-positive Breast Cancer
- Trial name
- TOUCH (NCT03644186)
- Testing
- Paclitaxel, Trastuzumab, Pertuzumab
- Where
- 54 sites in Belgium, France and 2 more
- Volunteers
- 147 people
- Sponsor
- ETOP IBCSG Partners Foundation
Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women
A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer
Estrogen is known to be a regulator of bone and lipid metabolism. Letrozole is a potent inhibitor of estrogen synthesis. This study evaluated the effects of letrozole and tamoxifen on bone and lipid metabolism in postmenopausal…
- Trial name
- NCT00171704
- Testing
- Letrozole, Tamoxifen
- Where
- 13 sites in Denmark, United Kingdom
- Volunteers
- 263 people
- Sponsor
- Novartis Pharmaceuticals
Uterine Fibroids
Pharmacokinetics and Hepatic Safety of EGCG
A trial to assess the pharmacokinetics and hepatic safety of EGCG in women with and without uterine fibroids.
- Trial name
- NCT04177693
- Testing
- Epigallocatechin gallate (EGCG), Clomiphene Citrate, Letrozole
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Yale University
Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
This phase II trial studies how well FASN inhibitor TVB-2640, paclitaxel, and trastuzumab work in treating patients with HER2 positive breast cancer that has spread to other places in the body (metastatic).
- Conditions
- Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
- Trial name
- NCT03179904
- Testing
- Anastrozole, Denifanstat, Exemestane
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
Study to evaluate the safety, tolerability, antitumor activity, and pharmacology of MEDI-573 in combination with an aromatase inhibitor (AI) in adult subjects with HR+, HER2-negative MBC.
- Trial name
- NCT01446159
- Testing
- MEDI-573, Aromatase Inhibitor
- Where
- 71 sites in United States, Belgium and 9 more
- Volunteers
- 188 people
- Sponsor
- MedImmune LLC
Metastatic Breast Cancer
Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.
The purpose of this study is to determine if acquired hormone therapy resistance can be reversed by Avastin (Bevacizumab), as measured by time to disease progression and evaluate toxicity of the combination of hormone treatment…
- Trial name
- NCT00240071
- Testing
- Avastin, Hormonal therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
Advanced, Metastatic Breast Cancer
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer
The primary purpose of this study was to assess the efficacy of ribociclib, as measured by progression free survival (PFS), in postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2…
- Trial name
- MONALEESA-2 (NCT01958021)
- Testing
- Ribociclib, Letrozole
- Where
- 221 sites in United States, Argentina and 27 more
- Volunteers
- 668 people
- Sponsor
- Novartis Pharmaceuticals